TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01295853

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: t3 sympathicotomy
Description: The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: t4 symapthicotomy
Description: The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: t4 symapthicotomy
Description: The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
Study: NCT02166138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Abilative Laser treatment
Description: Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
Study: NCT04341740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: bone marrow aspiration
Study: NCT00946803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Cognitive-Behavioral Intervention
Description: Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
Study: NCT02539485

Intervention type: OTHER
Group type: OTHER
Intervention: heating precondition
Description: The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
Study: NCT03659656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle coaching
Description: Goal setting and behavior change barriers will be discussed through lifestyle behavioral change coaching. Personalized weekly physical activity achievement report will also be sending to participants in experimental group. The participants will also have a Fitbit to use for 3 months.

Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit usage
Description: The participants will have a Fitbit to use for 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit usage
Description: The participants will have a Fitbit to use for 3 months.
Study: NCT04408404

Intervention type: PROCEDURE
Intervention: Acute aortic dissection
Description: Acute aortic dissection treatment include Bentall procedure, Tyrone David procedure, Yacoub procedure or ascendant aortic replacement with or without aortic valve replacement, ascendant aortic root remodelling (all are standard of care procedures)
Study: NCT01346163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF 03654746
Description: All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be used as a comparator to the active arm.
Study: NCT02349893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA treatment
Description: RFA treatment using CelonProSleep plus system
Study: NCT03252964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Tracker
Description: Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
Study: NCT03401112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: Oral administration of IMR-687 once daily with or without HU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: Oral administration of IMR-687 once daily with or without HU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo once daily with or without HU.
Study: NCT03706989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG samples will be recorded before and during the cardiac surgery in order to perform spectral and coherence analyses

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Apolipoprotein genotype
Description: APOE genotyping will be performed for each patient

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serum NfL measurements
Description: 5 perioperative blood samples will be taken to measure the evolution of NfL in the serum (before and until postoperative day 5)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative neurocognitive evaluation
Description: Each patient will benefit from a complete neurocognitive evaluation before surgery (battery of validated cognitive tests)
Study: NCT00482521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Description: Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
Study: NCT02458638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Description: Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
Study: NCT02091882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo-embedded IEM tablet.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
Description: Combination product of aripiprazole tablet embedded with sensor and wearable patch with MIND1 system on smartphone
Study: NCT01027780

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
Study: NCT03199274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Microsphere Radioembolization
Description: Undergo standard of care Y-90 radioembolization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yttrium-90 Microsphere Radioembolization
Description: Undergo standard of care Y-90 radioembolization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Protein-Type A Microspheres
Description: Given IV.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Ultrasound Imaging
Description: Undergo CEUS
Study: NCT05046548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine for intramuscular injection
Description: Volunteers (10 at the Stage 1; 140 at the Stage 2; 150 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator (without active ingredient) for intramuscular injection
Description: Volunteers (5 at the Stage 1; 45 at the Stage 2; 50 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
Study: NCT02304809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
Study: NCT00115882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI + CBST
Description: The HS Study intervention consisted of proactive identification and recruitment of eligible smokers (and selected nonsmokers) within the target population, and a protocol-guided series of counselor-initiated, personally-tailored telephone calls (from 1 to 10, depending on participant's interest) to eligible high school senior smokers and nonsmokers in experimental high schools. The telephone-delivered behavioral intervention integrated Motivational Interviewing and Cognitive Behavioral Skills building. Content and dose were tailored to the individual.
Study: NCT01416766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring-nurse-primary care provider feedback loop
Description: Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
Study: NCT03461354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MucoLox
Description: MucoLox formulation, with MucoLox as the delivery vehicle, combined with preserved water, beta-glucan, dexpanthenol, and glutamine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Sodium bicarbonate oral rinse
Study: NCT01297036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil, ODT 10 mg
Description: Test- Donepezil Hydrochloride 10 mg Tablet single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil, 10 mg tablet
Description: Reference: Donepezil Hydrochloride 10 mg Tablet
Study: NCT01345045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-639
Description: ABT-639 Twice Daily for six weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 6 weeks.
Study: NCT03651765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Once daily subcutaneous injection
Study: NCT03364647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm A - blood flow restriction training
Description: Group receive standard of care plus blood flow restriction training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Arm B - standard of care
Description: Group will receive standard of care plus a sham version of blood flow restriction training
Study: NCT00551499

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT + AOP
Description: The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
Study: NCT02735174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor cap system for inhalers
Description: All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App for SmartPhone
Description: All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviews
Description: All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth clinic visits
Description: All subjects will have asthma medical visits via telehealth technology to assess asthma control.
Study: NCT01706471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus + Low dose CsA +PD
Description: Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up \>3 ng/mL. Steroid dose follows local protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic+ Standard CsA + PD
Description: Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
Study: NCT02706236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pancrelipase
Description: Oral Pancrelipase, 720,000 units spread throughout the day with meals and snacks, taken daily PO for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
Study: NCT02556944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with multifocal intraocular lens
Description: Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
Study: NCT02689297

Intervention type: OTHER
Group type: OTHER
Intervention: chlorine dioxide
Description: First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.

Intervention type: OTHER
Group type: OTHER
Intervention: small toothbrush for tongue cleaning
Description: First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
Study: NCT04493723

Intervention type: PROCEDURE
Intervention: Surgery
Description: To collect tumour tissue

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: To collect blood samples
Study: NCT02936856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepatic Arteriography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic Arteriography
Study: NCT06159270

Intervention type: OTHER
Intervention: Blood sample
Description: Venuous blood sampling
Study: NCT02777060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Subjects will perform progressive and computerized foot and ankle exercises which include weight shifting, ankle reaching task while standing, and virtual obstacle crossing task (i.e. balancing on single leg) using wearable sensors technology (Exergaming) equipment). Subjects will perform these exercises for 4-6 weeks, twice per week. The duration of exercise per session is anticipated to be 30-45 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home based balance training
Description: Subjects in the control group will ask to perform a standard home based balance program for 4-6 weeks. The home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback and Exergaming equipment.
Study: NCT00637299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active osteopathic treatment (OMT+PR): Active Comparator
Description: The treatment was done once a week for 4 weeks and lasted 30 minutes.The examination was done according to the following scheme: anamnesis; physical examination (evaluation of the posture, palpation, tests for passive and active motion of areas linked to altered respiratory function); cranic-sacral evaluation (by means of a palpation of the cranic-sacral mechanism).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham osteopathic treatment (SOT+PR)
Description: Only soft manipulation was performed
Study: NCT03741348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: In (ES) group After skin sterilization, ESPB was performed in sitting position at the level of T9 linear ultrasound (US) transducer (Phillips-Saronno Italy) was placed vertically 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between the two transverse processes. After local infiltration of needle insertion site with 2-3ml of 2% lidocaine, a 22-gauge Short bevel needle (Spinocan, B.Braun Melsungen AG, Germany) was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles. Then, up to 20 ml of bupivacaine 0.5% was injected. The procedure was repeated following the same steps on the other side of back.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: in control group, Erector Spinae Plane Block will not be done
Study: NCT03773848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation (ORIF)
Description: Open Reduction Internal Fixation (ORIF) of fracture lateral third clavicle by hook plate \& tightrope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation (ORIF)
Description: Open Reduction Internal Fixation (ORIF) of fracture lateral third clavicle by hook plate \& tightrope
Study: NCT00927992

Intervention type: OTHER
Intervention: Epidemiological Non interventional
Description: Epidemiological Non interventional
Study: NCT02648607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customised Dynamic Elastomeric Fabric Orthosis (DEFO)
Description: Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthosis (DEFO). Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
Study: NCT04351204

Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy
Description: multiple new techniques and software for MR-guided adaptive radiation therapy.
Study: NCT00909493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Network Access
Description: Primary Care Physicians in this treatment group will have access to a pain specialist at the Pain Management Unit.
Study: NCT01190748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine 4 mg Tablet, single dose
Description: A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reminyl 4 mg Tablet, single dose
Description: B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions